Array BioPharma Reports Results of Combination Therapy in P-III BEACON CRC Study for BRAF(V600E)- Mutant Metastatic Colorectal Cancer
Shots:
- The P-III BEACON CRC study results involves assessing of Braftovi (encorafenib) + Erbitux (cetuximab)- with/without Mektovi (binimetinib) vs Erbitux and irinotecan-based therapy in 665 patients with BRAFV600E-mutant metastatic colorectal cancer- prior treated with 1L & 2L therapies
- P-III BEACON CRC study results: Braftovi triplet & doublet- improvement in ORR (26.1% vs 1.9% & 20.4% vs 1.9%); OS (9.0 mos. vs 5.4 mos. & 8.4 mos. vs 5.4mos.); ORR assessed by BICR (34.3% & 22.4%) respectively; triple combination reduces the risk of death by 48%
- Array’s Braftovi & Mektovi is BRAF kinase & MEK inhibitor respectively while Eli Lilly’s Erbitux is an EGFR inhibitor. In Aug’18 the triplet combination therapy receives FDA’s BT designation & plans to submit results of the BEACON CRC study for marketing approval in H2’19
Ref: Array Biopharma | Image: Condit Exhibits
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com